# Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1

Source: https://onco.cc/trials/nct05383482/  
OnCo record `nct05383482` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Afuresertib run by Laekna Limited, completed.

## Summary

Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1 is a phase 1/2 interventional study registered as NCT05383482 by Laekna Limited, with 22 participants enrolled, started 2022-07-01, primary completion reached 2024-06-25. Conditions recorded: Solid Tumor, NSCLC, Cervical Cancer, Endometrial Cancer, Esophageal Cancer, Gastric and Gastroesophageal Junction Adenocarcinoma. Interventions recorded: Afuresertib, Nab paclitaxel, Docetaxel, Sintilimab.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-11-04
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05383482
- Phase: 1/2
- Setting: A Phase I/II Dose-Escalation and Efficacy/Safety Study of Afuresertib Plus Sintilimab Plus Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1 Treatment
- Sponsor: Laekna Limited
- Enrolled: 22

## Sources

- ClinicalTrials.gov NCT05383482: https://clinicaltrials.gov/study/NCT05383482

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Afuresertib](https://onco.cc/drugs/afuresertib/)
- companies: [Laekna Therapeutics](https://onco.cc/companies/laekna-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct05383482.json